Ranking Invest

Kiniksa Pharmaceuticals, Ltd.

Segmento: Healthcare Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Indicadores Básicos

Valor de Mercado

$ 2.46 Bi

IVR

0.21

IVR2

0.02

Índices de Previsibilidade

Faturamento

0.18

Lucro

1.99

Margem

1.91

Índices de Tendência

Faturamento

10.99

Lucro

7.90

Margem

5.50

Índices de Endividamento

DIV/PAT

-0.32

DIV/L4T

8.69

Dívida Líquida

-$ 147.22 Mi

Patrimônio Líquido

$ 457.49 Mi

L4T

-$ 16.95 Mi

MM4T

-3.99%

Dívidas
Dividendos
Cotação: $33.15

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre